Siegfried Holding acquires Noramco, Extractas and Purisys from SK Capital

SK Capital has exited its controlled-substances pharmaceutical platform, selling Noramco, Extractas Biosciences, and Purisys to Swiss contract development and manufacturing organization Siegfried Holding.

The private equity firm retains Halo Pharmaceuticals, a North American finished-dose CDMO.

Noramco produces active pharmaceutical ingredients for pain management, addiction treatment, and attention-deficit/hyperactivity disorder therapies.

Extractas supplies narcotic raw materials from its poppy extraction operation in Tasmania, serving the global opioid and alkaloid supply chain.

Purisys develops and manufactures synthetic cannabinoid APIs and controlled-substance intermediates for clinical and commercial use.

For Siegfried, the transaction adds a DEA-regulated API manufacturing presence in North America.

The Zofingen-based CDMO operates development and production sites in Switzerland, the United States, Germany, France, Spain, and Malta, supplying pharmaceutical and biotech customers across more than 100 markets.

SK Capital built the platform by combining the three businesses into a vertically integrated controlled-substances provider.

The New York investment firm will now direct its pharmaceutical efforts through Halo, focusing on finished-dose manufacturing in the U.S. and Canada.